Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

liposome-encapsulated TAAs mRNA vaccine W_ova1

A vaccine consisting of messenger RNA (mRNA) encoding three tumor-associated antigens (TAAs) specific for ovarian cancer that are encapsulated in liposomes, with potential immunomodulating and antineoplastic activities. Upon administration of the liposome-encapsulated TAAs mRNA vaccine W_ova1, the liposomes bind to the plasma membrane of cells and release the mRNA into the cells. The mRNA is then translated by ribosomes to produce the TAAs. The TAAs are presented to the immune system which may activate both humoral and cellular immune responses against the ovarian cancer cells expressing these TAAs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:liposome-formulated mRNA vaccine W_ova1
mRNA vaccine W_ova1
W_ova1 vaccine
Code name:BNT-115
W_ova1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search